<DOC>
	<DOC>NCT02978196</DOC>
	<brief_summary>To evaluate the efficacy and safety of 99m-Tc labeled anti-PD-L1 VHH for SPECT/CT diagnostic imaging of Non-Small Cell Lung Cancer and compare it with the existing gold standard "biopsy PD-L1 detection". It is also to establish a new method of clinical diagnosis of NSCLC using 99m-Tc labeled anti-PD-L1 VHH.</brief_summary>
	<brief_title>99m-Tc Labeled Anti-PD-L1 VHH for Diagnostic Imaging of Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Participant is willing and able to give informed consent for the participation in the study before any protocolspecific screening procedures are performed Male or female, aged 1875 years old Previous diagnosis of nonsmall cell carcinoma, confirmed with pathology tests AST, ALT, BUN, Cr not more than double the normal values Patients with no current history of hepatitis A, hepatitis B, AIDS, tuberculosis and other infectious diseases Severe infection PDL1 expression level undetermined Patients with pacemakers Pregnant and lactating women Investigators professional decision that the subject should not participate in this clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>